Please provide your email address to receive an email when new articles are posted on . Laurenzano, Marinkovic and colleagues conducted a retrospective study analyzing subcutaneous testosterone as ...

EWING, N.J., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the approval of XYOSTED ™ (testosterone enanthate) injection by the U.S. Food and Drug Administration ...

Please provide your email address to receive an email when new articles are posted on . In female-to-male transgender patients, subcutaneous testosterone therapy was safe and effective and was the ...

The US Food and Drug Administration (FDA) has approved testosterone enanthate (Xyosted, Antares Pharma) subcutaneous injection for testosterone replacement therapy in men diagnosed with conditions ...

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from a multi-center phase 2 clinical study evaluating the pharmacokinetic profile of testosterone ...

The BLA is based on LEQEMBI subcutaneous (SC) sub-studies of the Phase 3 Clarity AD open-label extension (OLE) trial in individuals with early AD, which evaluated a range of subcutaneous doses. Data ...

Medicus Pharma is advancing Teverelix, a recently acquired, clinical stage asset, designed to address limitations of current ...

Xyosted (testosterone enanthate) is a brand-name drug that’s prescribed to treat testosterone deficiency in adults. Xyosted comes as a solution in a prefilled auto-injector pen. It’s typically given ...

STOCKHOLM, Aug. 29, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA-B) partner Eisai announced today the U.S. Food and Drug Administration (FDA) has approved the Biologics License ...